| Document Date: 2015-03-26 07:09:24
Open Document File Size: 2,87 MBShare Result on Facebook
City Zug / / Company ANNUAL REPORT 2014 SHIRE PLC / ViroPharma / SHIRE SHIRE SHI SH H RE PLC / Fibrotech / NPS Pharma / Lumena / BIKAM Pharmaceuticals / ArmaGen / SHIRE PLC / MPH / / Continent Africa / Europe / / Country Switzerland / Japan / United States / / Currency USD / / Event Company Expansion / M&A / Business Partnership / Reorganization / Funding / / Facility US Operational Headquarters / International Operational Headquarters / Ophthalmics pipeline / / Holiday D Day / / IndustryTerm therapies for Short Bowel Syndrome / treatment of Binge Eating Disorder / a rare disease treatment / intrathecal delivery device / cash-generating specialty products / / MedicalCondition capabilities Ophthalmics Rare Diseases / rare diseases / Hyperparathyroidism / HAE / focal segmental glomerulosclerosis / Hunter syndrome / ADHD / rare gastrointestinal/hepatic diseases / rare disease / Attention Deficit Hyperactivity Disorder / autosomal dominant retinitis pigmentosa / Short Bowel Syndrome / eating disorder / Binge Eating Disorder / strong rare diseases / / MedicalTreatment enzyme replacement therapies / / Organization Governance Board / US Census Bureau / FDA / / Person Flemming Ornskov / Moving One / / Position Chief Executive Officer Financial Statements / Chief Executive / Heading Chief Executive / Chief Executive Officer / RT / review Chief Executive Officer / leader / Chairman / Hunter / forward / / Product LIALDA / VYVANSE / AGRYLIN / / ProvinceOrState Massachusetts / / RadioStation 2014 RT 2014 / / Region Middle East / / Technology Neuroscience / /
SocialTag |
Annual ReportOur journey forward At Shire we have a clear and focused strategy to become a leading global biotech delivering